New data clarify apomorphine vs ropinirole for canine emesis

CURRENT FULL VERSION: A new comparative study is giving veterinary professionals better data on a question many clinics have been answering from experience: when should you reach for apomorphine, and when does ropinirole make more sense? In a March 17, 2025, Frontiers in Veterinary Science paper, researchers reported that ophthalmic ropinirole was as effective as IV apomorphine for inducing emesis in 24 healthy dogs, but the two drugs differed meaningfully in speed and adverse-effect profile. (frontiersin.org)

That matters because the market and regulatory landscape have changed over the past few years. Ropinirole ophthalmic solution, marketed as Clevor, became the first FDA-approved emetic for dogs in June 2020. By contrast, apomorphine remains a familiar but extra-label option in U.S. practice, with routes including IV, SC, IM, subconjunctival, and oral use, and it is commonly compounded from bulk drug powder. University of Illinois pharmacy guidance has framed the choice as a balance between FDA labeling, route of administration, speed, and safety, noting that apomorphine can act in 1 to 5 minutes IV, while ropinirole typically takes around 12 minutes. (fda.gov)

In the 2025 Frontiers crossover trial, both agents performed well on the core endpoint. Emesis success was 23 of 24 dogs for apomorphine and 24 of 24 for ropinirole, with no significant difference overall. But apomorphine was clearly faster, with a median time to first emesis of 1 minute 30 seconds versus 7 minutes 37 seconds for ropinirole. Dogs receiving ropinirole also had more vomiting episodes, a longer duration of vomiting, and a much higher rate of early antiemetic use after more than three emetic episodes. Investigators concluded that the drugs had similar efficacy, but ropinirole carried more ocular redness and more protracted vomiting. (frontiersin.org)

Those findings line up, at least in part, with other recent literature. A 2025 Journal of Veterinary Emergency and Critical Care study comparing ropinirole eye drops with IV apomorphine in an emergency setting also found similar overall efficacy, but reported a median time to first emetic event of 8.6 minutes for ropinirole and 1.6 minutes for apomorphine. As summarized by VetGirl, that prospective randomized clinical trial enrolled 132 client-owned dogs across two specialty referral hospitals from October 2021 to March 2023 after suspected or confirmed ingestion of a toxin or foreign body. Dogs were excluded if they were younger than 4.5 months, weighed less than 1.8 kg, had ocular disease, CNS or hepatic disease, had ingested a contraindicated substance such as a caustic or volatile agent, or had already received antiemetics. Cases included toxic foods, plants, medications, rodenticides, and foreign material ranging from toys and cords to cloth items. Dogs were randomized to ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs), with a second identical dose allowed if vomiting had not occurred within 20 minutes, and monitored for 40 minutes for emesis success, time to first emetic event, number of emetic events, and need for rescue antiemetics. Another 2024 clinical trial from Tufts concluded that intranasal and IV apomorphine outperformed ropinirole ocular drops for inducing emesis within 10 minutes. Taken together, the emerging evidence suggests that ropinirole can match apomorphine on eventual success, while apomorphine still appears to have an edge when rapid onset is the priority. (pubmed.ncbi.nlm.nih.gov)

Expert and industry commentary has largely focused on those practical tradeoffs. University of Illinois pharmacy guidance notes that ropinirole’s FDA-approved status and eye-drop delivery can make it attractive, especially compared with compounded apomorphine, which also raises hazardous-drug handling concerns. At the same time, that same guidance warns that apomorphine has been associated with more serious CNS and respiratory depression, while ropinirole appears more tolerable overall, though its labeled use is limited to dogs at least 4.5 months old and at least 1.8 kg. That makes patient selection, not just drug preference, central to the decision. (vetmed.illinois.edu)

Why it matters: For veterinary professionals, this is a workflow story as much as a pharmacology story. In toxin ingestion cases, a 6- to 7-minute difference in onset may be clinically important for rapidly absorbed exposures, and the Frontiers authors explicitly note that apomorphine’s faster onset could matter in those scenarios. But many practices may still prefer ropinirole in appropriate patients because it is on-label, easy to administer, and avoids the need to stock or compound injectable apomorphine. The downside is that clinics should be prepared for more vomiting episodes, ocular irritation, and the possibility of follow-up antiemetic support. In the emergency-setting study summarized by VetGirl, rescue antiemetics were built into the protocol after induction attempts, reinforcing that emesis induction and emesis control often need to be considered together in real-world toxicology workflows. (frontiersin.org)

There’s also a broader formulary context here. While your source set included Dechra’s 2025 FDA approval of Emeprev, that product is an antiemetic, not an emetic. Emeprev is a bioequivalent injectable maropitant for dogs and cats, approved in December 2025, with benzyl alcohol as a preservative and room-temperature storage, and it is expected to be available through major distributors in early 2026. Additional product coverage has emphasized two practical points for clinics: the benzyl alcohol preservative appears to reduce injection pain in dogs compared with the pioneer drug, and the no-refrigeration requirement may simplify storage and workflow. Emeprev is indicated for prevention and treatment of acute vomiting in dogs and for treatment of vomiting in cats, with SC or IV administration in adults and SC use in puppies 2 to 4 months old. That launch underscores how fast the nausea-and-vomiting category is evolving, but it addresses vomiting control after the fact, not induction of emesis for decontamination. For clinicians, keeping those roles distinct is important when evaluating product news and treatment protocols. (dechra-us.com)

What to watch: The next step is likely more real-world protocol refinement, especially in emergency settings and poison-response workflows, where case type, timing of ingestion, patient size and age, ocular status, and staff comfort with compounded hazardous drugs will determine whether clinics standardize around ropinirole, keep apomorphine as first-line for select cases, or use both. (pubmed.ncbi.nlm.nih.gov)